Indication
Hypopharyngeal Squamous Cell Carcinoma
17 clinical trials
18 products
7 drugs
Clinical trial
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)Status: Recruiting, Estimated PCD: 2025-07-31
Product
PeposertibClinical trial
A Window of Opportunity Trial of NT-I7 in Patients With Locally Recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Salvage SurgeryStatus: Recruiting, Estimated PCD: 2025-03-31
Product
Efineptakin alfaClinical trial
Early-Phase Open-label Study of Tolinapant and Radiation in Cisplatin-Ineligible Patients With Previously Untreated, Locally Advanced Head and Neck CancerStatus: Recruiting, Estimated PCD: 2025-10-21
Product
TolinapantClinical trial
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Product
CabozantinibProduct
NivolumabClinical trial
Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck CancerStatus: Completed, Estimated PCD: 2020-10-06
Drug
TiragolumabDrug
AN0025Clinical trial
Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsStatus: Recruiting, Estimated PCD: 2025-06-01
Product
PembrolizumabProduct
CarboplatinProduct
PaclitaxelClinical trial
A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell CancerStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Product
SorafenibClinical trial
A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Recruiting, Estimated PCD: 2024-12-31
Product
CemiplimabClinical trial
Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-11-27
Product
ElimusertibDrug
mFOLFOX6Clinical trial
A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With CisplatinStatus: Completed, Estimated PCD: 2023-05-31
Drug
CisplatinClinical trial
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-07-05
Product
IRX-2Clinical trial
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to CisplatinStatus: Active (not recruiting), Estimated PCD: 2022-09-20
Drug
AtezolizumabDrug
VarlilumabClinical trial
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck CancerStatus: Completed, Estimated PCD: 2016-10-29
Product
CetuximabProduct
IpilimumabClinical trial
ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response EvaluationStatus: Not yet recruiting, Estimated PCD: 2028-12-01
Drug
pembrolizumabClinical trial
Smoking Cessation in Patients With Squamous Cell Cancer of the Head and Neck Undergoing Radiation Therapy With or Without ChemotherapyStatus: Terminated, Estimated PCD: 2018-10-06
Product
BupropionProduct
Nicotine ReplacementProduct
VareniclineClinical trial
A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckStatus: Recruiting, Estimated PCD: 2025-06-30
Product
IpatasertibClinical trial
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHNStatus: Active (not recruiting), Estimated PCD: 2024-01-05